Cargando…

Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells

SIMPLE SUMMARY: Tumor-infiltrating lymphocytes (TILs) are likely to play a role in the biological behavior of HER2+ ductal carcinoma in situ (DCIS). To prevent invasiveness, the potential of targeted immune-modulating treatment of HER2+ DCIS has been explored. We identified a 29-gene expression prof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agahozo, Marie Colombe, Smid, Marcel, van Marion, Ronald, Hammerl, Dora, van den Bosch, Thierry P. P., Timmermans, Mieke A. M., Heijerman, Chayenne J., Westenend, Pieter J., Debets, Reno, Martens, John W. M., van Deurzen, Carolien H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389698/ https://www.ncbi.nlm.nih.gov/pubmed/34440000 http://dx.doi.org/10.3390/biology10080768

Ejemplares similares

Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast
por: Agahozo, Marie Colombe, et al.
Publicado: (2022)

A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast
por: Van Bockstal, Mieke R., et al.
Publicado: (2019)

Radioactive Seed Versus Wire-Guided Localization for Ductal Carcinoma in Situ of the Breast: Comparable Resection Margins
por: Agahozo, Marie Colombe, et al.
Publicado: (2020)

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
por: Van Bockstal, Mieke R., et al.
Publicado: (2020)

Loss of Y-Chromosome during Male Breast Carcinogenesis
por: Agahozo, Marie Colombe, et al.
Publicado: (2020)

APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
por: van den Ende, Nadine S., et al.
Publicado: (2022)

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
por: Hammerl, Dora, et al.
Publicado: (2021)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
por: van den Ende, Nadine S., et al.
Publicado: (2023)

Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation
por: Braakman, René B. H., et al.
Publicado: (2017)

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017)

Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response
por: Liu, Ning Qing, et al.
Publicado: (2014)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Bastiaansen, Anna E. M., et al.
Publicado: (2020)

Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study
por: van Deurzen, Carolien H. M.
Publicado: (2016)

Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing
por: Doebar, S. C., et al.
Publicado: (2018)

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
por: Doebar, Shusma C., et al.
Publicado: (2016)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)

Real-world data of HER2-low metastatic breast cancer: A population based cohort study
por: Holthuis, Emily I., et al.
Publicado: (2022)

Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries—Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients
por: de Koning, Willem, et al.
Publicado: (2023)

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019)

Carcinoma in situ to invasive breast cancer
por: van Deurzen, Carolien H.M., et al.
Publicado: (2015)

Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients
por: van den Berg, Inge, et al.
Publicado: (2021)

A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer
por: van den Berg, Inge, et al.
Publicado: (2021)

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients
por: Liu, Ning Qing, et al.
Publicado: (2016)

Using second harmonic generation to predict patient outcome in solid tumors
por: Burke, K., et al.
Publicado: (2015)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome
por: de Kruijff, Ingeborg E., et al.
Publicado: (2018)

High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes
por: Riaz, Muhammad, et al.
Publicado: (2012)

Temporal Contiguity Training Influences Behavioral and Neural Measures of Viewpoint Tolerance
por: Van Meel, Chayenne, et al.
Publicado: (2018)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Surgeons’ preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ
por: Meurs, Claudia J. C., et al.
Publicado: (2022)

Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model
por: Meurs, Claudia J. C., et al.
Publicado: (2022)

Validation and Clinical Utility of a Prediction Model for the Risk of Upstaging to Invasive Breast Cancer After a Biopsy Diagnosis Ductal Carcinoma In Situ
por: Meurs, Claudia J. C., et al.
Publicado: (2023)

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
por: Siddiqui, Imran, et al.
Publicado: (2016)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohort
por: Akdeniz, Delal, et al.
Publicado: (2022)

A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers
por: Meurs, Claudia J. C., et al.
Publicado: (2018)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

Elastosis in ERα-positive male breast cancer
por: Vermeulen, Marijn A., et al.
Publicado: (2020)

RE: Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ
por: Meurs, Claudia J C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pg4i21668u03f08if8207o6nl4